Literature DB >> 11704725

Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections.

A S Meyerhoff1, B G Weniger, R J Jacobs.   

Abstract

BACKGROUND: One reason that recommended childhood immunizations due at child health visits are deferred is to avoid the pain and emotional distress associated with the increasing number of injections required. This deferral leads to additional visits and costs and reduced immunoprotection against vaccine-preventable illnesses. To assess the economic value of combination vaccines that address this problem, we surveyed parents to determine the amount they would be willing to pay to avoid the pain and emotional distress experienced by their infants from injections.
METHODS: A self-administered questionnaire was completed within 24 h of the vaccinations by 294 parents of children ages 11/2 to 7 months receiving vaccine injections at 26 outpatient child health centers. The willingness-to-pay (WTP) method was used to estimate the intangible cost of the pain and emotional distress of the 1 to 4 injections their child had received. Parents were asked how much of their own money they would have paid to avoid these injections, without any compromise in the safety and efficacy of the vaccinations.
RESULTS: Wide variations in WTP amounts were observed, ranging from median values of $10 to $25 and average values of $57.06 to $79.28 to avoid the pain and emotional distress associated with eliminating all injections at visits in which one to four injections were administered. Parents placed greater value on reductions that avoided all injections than on reductions that avoided only some injections. Overall the median cost per injection avoided was $8.14, and the mean was $30.28.
CONCLUSIONS: Parents have strong preferences for limiting vaccine injections. The economic cost of the pain and distress associated with such injections, reflected in the amounts they report they would be willing to pay to avoid them, represents a substantial component of the cost of disease control through immunization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704725     DOI: 10.1097/00006454-200111001-00009

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  18 in total

1.  Using Monte Carlo simulation to determine combination vaccine price distributions for childhood diseases.

Authors:  Sheldon H Jacobson; Edward C Sewell
Journal:  Health Care Manag Sci       Date:  2002-04

2.  Pricing strategies for combination pediatric vaccines and their impact on revenue: Pediarix or Pentacel?

Authors:  Matthew J Robbins; Sheldon H Jacobson; Edward C Sewell
Journal:  Health Care Manag Sci       Date:  2010-03

Review 3.  Reducing the pain of childhood vaccination: an evidence-based clinical practice guideline.

Authors:  Anna Taddio; Mary Appleton; Robert Bortolussi; Christine Chambers; Vinita Dubey; Scott Halperin; Anita Hanrahan; Moshe Ipp; Donna Lockett; Noni MacDonald; Deana Midmer; Patricia Mousmanis; Valerie Palda; Karen Pielak; Rebecca Pillai Riddell; Michael Rieder; Jeffrey Scott; Vibhuti Shah
Journal:  CMAJ       Date:  2010-11-22       Impact factor: 8.262

Review 4.  The value of childhood combination vaccines: From beliefs to evidence.

Authors:  Khaled Maman; York Zöllner; Donato Greco; Gerard Duru; Semukaya Sendyona; Vanessa Remy
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Emotions and scope effects in the monetary valuation of health.

Authors:  María V Avilés Blanco; Raúl Brey; Jorge Araña; José Luis Pinto Prades
Journal:  Eur J Health Econ       Date:  2017-03-24

6.  Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer.

Authors:  Marie-Chantal Ethier; Dean A Regier; Deborah Tomlinson; Peter Judd; John Doyle; Adam Gassas; Ahmed Naqvi; Lillian Sung
Journal:  Support Care Cancer       Date:  2011-09-25       Impact factor: 3.603

7.  A willingness-to-pay assessment of parents' preference for shorter duration treatment of acute otitis media in children.

Authors:  Delphine Gueylard Chenevier; Jacques LeLorier
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Engineering the economic value of two pediatric combination vaccines.

Authors:  Sheldon H Jacobson; Edward C Sewell; Tamana Karnani
Journal:  Health Care Manag Sci       Date:  2005-02

9.  Preferences for health outcomes associated with Group A Streptococcal disease and vaccination.

Authors:  Grace M Lee; Joshua A Salomon; Charlene Gay; James K Hammitt
Journal:  Health Qual Life Outcomes       Date:  2010-03-12       Impact factor: 3.186

10.  Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule.

Authors:  Francis Fagnani; Camille Le Fur; Isabelle Durand; Michel Gibergy
Journal:  Eur J Health Econ       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.